{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T14:24:52Z","timestamp":1778509492614,"version":"3.51.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s12325-025-03104-y","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T01:30:27Z","timestamp":1740706227000},"page":"1860-1880","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Population Pharmacokinetics of Niraparib\/Abiraterone Acetate Administered as Single-Agent Combination and Dual-Acting Tablets Plus Prednisone for Metastatic Castration-Resistant Prostate Cancer"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2095-4365","authenticated-orcid":false,"given":"Alberto","family":"Russu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anasuya","family":"Hazra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nahor","family":"Haddish-Berhane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9890-745X","authenticated-orcid":false,"given":"Juan Jose","family":"Perez Ruixo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muriel","family":"Boulton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,28]]},"reference":[{"key":"3104_CR1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djx030","author":"A Jemal","year":"2017","unstructured":"Jemal A, Ward EM, Johnson CJ, Cronin KA, Ma J, Ryerson B, et al. Annual report to the nation on the status of cancer, 1975\u20132014, featuring survival. J Natl Cancer Inst. 2017. https:\/\/doi.org\/10.1093\/jnci\/djx030.","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"3104_CR2","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.euf.2019.01.016","volume":"5","author":"A Davies","year":"2019","unstructured":"Davies A, Conteduca V, Zoubeidi A, Beltran H. Biological evolution of castration-resistant prostate cancer. Eur Urol Focus. 2019;5(2):147\u201354. https:\/\/doi.org\/10.1016\/j.euf.2019.01.016.","journal-title":"Eur Urol Focus"},{"key":"3104_CR3","unstructured":"American Cancer Society. Prostate cancer early detection, diagnosis, and staging. November 23, 2023. https:\/\/www.cancer.org\/cancer\/prostate-cancer\/detection-diagnosis-staging.html. Accessed December 2, 2024."},{"issue":"2","key":"3104_CR4","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.cell.2015.05.001","volume":"162","author":"D Robinson","year":"2015","unstructured":"Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;162(2):454. https:\/\/doi.org\/10.1016\/j.cell.2015.05.001.","journal-title":"Cell"},{"issue":"11","key":"3104_CR5","doi-asserted-by":"publisher","first-page":"3094","DOI":"10.1158\/1078-0432.CCR-20-4805","volume":"27","author":"H Tukachinsky","year":"2021","unstructured":"Tukachinsky H, Madison RW, Chung JH, Gjoerup OV, Severson EA, Dennis L, et al. Genomic analysis of circulating tumor DNA in 3,334 patients with advanced prostate cancer identifies targetable BRCA alterations and AR resistance mechanisms. Clin Cancer Res. 2021;27(11):3094\u2013105. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-4805.","journal-title":"Clin Cancer Res"},{"issue":"15_suppl","key":"3104_CR6","doi-asserted-by":"publisher","first-page":"5002","DOI":"10.1200\/JCO.2017.35","volume":"35","author":"KN Chi","year":"2017","unstructured":"Chi KN, Annala M, Sunderland K, Khalaf D, Finch D, Oja CD, et al. A randomized phase II cross-over study of abiraterone + prednisone (ABI) vs enzalutamide (ENZ) for patients (pts) with metastatic, castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2017;35(15_suppl):5002. https:\/\/doi.org\/10.1200\/JCO.2017.35.","journal-title":"J Clin Oncol"},{"issue":"6","key":"3104_CR7","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1200\/JCO.18.00358","volume":"37","author":"E Castro","year":"2019","unstructured":"Castro E, Romero-Laorden N, Del Pozo A, Lozano R, Medina A, Puente J, et al. PROREPAIR-B: A prospective cohort study of the impact of germline DNA repair mutations on the outcomes of patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2019;37(6):490\u2013503. https:\/\/doi.org\/10.1200\/JCO.18.00358.","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"3104_CR8","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1002\/pros.24352","volume":"82","author":"P Cresta Morgado","year":"2022","unstructured":"Cresta Morgado P, Mateo J. Clinical implications of homologous recombination repair mutations in prostate cancer. Prostate. 2022;82(Suppl 1):S45\u201359. https:\/\/doi.org\/10.1002\/pros.24352.","journal-title":"Prostate"},{"key":"3104_CR9","doi-asserted-by":"publisher","first-page":"102359","DOI":"10.1016\/j.ctrv.2022.102359","volume":"104","author":"M Bienkowski","year":"2022","unstructured":"Bienkowski M, Tomasik B, Braun M, Jassem J. PARP inhibitors for metastatic castration-resistant prostate cancer: biological rationale and current evidence. Cancer Treat Rev. 2022;104:102359. https:\/\/doi.org\/10.1016\/j.ctrv.2022.102359.","journal-title":"Cancer Treat Rev"},{"issue":"18","key":"3104_CR10","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","volume":"373","author":"J Mateo","year":"2015","unstructured":"Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, et al. DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med. 2015;373(18):1697\u2013708. https:\/\/doi.org\/10.1056\/NEJMoa1506859.","journal-title":"N Engl J Med"},{"issue":"1","key":"3104_CR11","doi-asserted-by":"publisher","first-page":"e115","DOI":"10.1634\/theoncologist.2020-0697","volume":"26","author":"EN Risdon","year":"2021","unstructured":"Risdon EN, Chau CH, Price DK, Sartor O, Figg WD. PARP inhibitors and prostate cancer: to infinity and beyond BRCA. Oncologist. 2021;26(1):e115\u201329. https:\/\/doi.org\/10.1634\/theoncologist.2020-0697.","journal-title":"Oncologist"},{"issue":"2","key":"3104_CR12","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.molcel.2010.09.019","volume":"40","author":"A Ciccia","year":"2010","unstructured":"Ciccia A, Elledge SJ. The DNA damage response: making it safe to play with knives. Mol Cell. 2010;40(2):179\u2013204. https:\/\/doi.org\/10.1016\/j.molcel.2010.09.019.","journal-title":"Mol Cell"},{"issue":"8","key":"3104_CR13","doi-asserted-by":"publisher","first-page":"3302","DOI":"10.1021\/jm5018237","volume":"58","author":"P Jones","year":"2015","unstructured":"Jones P, Wilcoxen K, Rowley M, Toniatti C. Niraparib: a poly(ADP-ribose) polymerase (PARP) inhibitor for the treatment of tumors with defective homologous recombination. J Med Chem. 2015;58(8):3302\u201314. https:\/\/doi.org\/10.1021\/jm5018237.","journal-title":"J Med Chem"},{"key":"3104_CR14","unstructured":"Zejula (niraparib): prescribing information. April 2023. https:\/\/gskpro.com\/content\/dam\/global\/hcpportal\/en_US\/Prescribing_Information\/Zejula_Tablets\/pdf\/ZEJULA-TABLETS-PI-PIL.PDF#page=1. Accessed December 2, 2024."},{"key":"3104_CR15","unstructured":"Zejula (nariparib): summary of product characteristics. August 1, 2024. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/zejula-epar-product-information_en.pdf. Accessed December 2, 2024."},{"issue":"12","key":"3104_CR16","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1038\/sj.bjc.6601879","volume":"90","author":"A O'Donnell","year":"2004","unstructured":"O\u2019Donnell A, Judson I, Dowsett M, Raynaud F, Dearnaley D, Mason M, et al. Hormonal impact of the 17alpha-hydroxylase\/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer. 2004;90(12):2317\u201325. https:\/\/doi.org\/10.1038\/sj.bjc.6601879.","journal-title":"Br J Cancer"},{"key":"3104_CR17","unstructured":"Zytiga\u00ae (abiraterone acetate): Prescribing information. August 2021. https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/ZYTIGA-pi.pdf. Accessed December 2, 2024."},{"key":"3104_CR18","unstructured":"Zytiga (abiraterone acetate): Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/zytiga-epar-product-information_en.pdf. Accessed December 2, 2024."},{"issue":"4","key":"3104_CR19","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s40262-023-01340-5","volume":"63","author":"A Yu","year":"2024","unstructured":"Yu A, Hazra A, Jiao J, Hellemans P, Mitselos A, Russu A, et al. Demonstrating bioequivalence for two dose strengths of niraparib and abiraterone acetate dual-action tablets versus single agents: Utility of clinical study data supplemented with modeling and simulation. Clin Pharmacokinet. 2024;63(4):511\u201327. https:\/\/doi.org\/10.1007\/s40262-023-01340-5.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"3104_CR20","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00280-021-04249-7","volume":"88","author":"F Saad","year":"2021","unstructured":"Saad F, Chi KN, Shore ND, Graff JN, Posadas EM, Lattouf JB, et al. Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE). Cancer Chemother Pharmacol. 2021;88(1):25\u201337. https:\/\/doi.org\/10.1007\/s00280-021-04249-7.","journal-title":"Cancer Chemother Pharmacol"},{"key":"3104_CR21","doi-asserted-by":"publisher","first-page":"abstr 202","DOI":"10.1200\/JCO.2019.37.7_suppl.202","volume":"37","author":"MR Smith","year":"2019","unstructured":"Smith MR, Sandhu SK, Kelly WK, Scher HI, Efstathiou E, Lara P, et al. Phase II study of niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): preliminary results of GALAHAD. J Clin Oncol. 2019;37:abstr 202. https:\/\/doi.org\/10.1200\/JCO.2019.37.7_suppl.202.","journal-title":"J Clin Oncol"},{"issue":"3","key":"3104_CR22","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/S1470-2045(21)00757-9","volume":"23","author":"MR Smith","year":"2022","unstructured":"Smith MR, Scher HI, Sandhu S, Efstathiou E, Lara PN Jr, Yu EY, et al. Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2022;23(3):362\u201373. https:\/\/doi.org\/10.1016\/S1470-2045(21)00757-9.","journal-title":"Lancet Oncol"},{"issue":"5","key":"3104_CR23","doi-asserted-by":"publisher","first-page":"e309","DOI":"10.1093\/oncolo\/oyad008","volume":"28","author":"KN Chi","year":"2023","unstructured":"Chi KN, Fleshner N, Chiuri VE, Van Bruwaene S, Hafron J, McNeel DG, et al. Niraparib with abiraterone acetate and prednisone for metastatic castration-resistant prostate cancer: phase II QUEST study results. Oncologist. 2023;28(5):e309\u201312. https:\/\/doi.org\/10.1093\/oncolo\/oyad008.","journal-title":"Oncologist"},{"key":"3104_CR24","doi-asserted-by":"publisher","unstructured":"Chi K, Fleshner N, Chiuri VE, Scaranos, Van Bruwaene S, Hafron J, et al. MP27-17\u00b0 niraparib with abiraterone acetate and prednisone for metastatic castration-resistant prostate cancer: Results from the phase 2 QUEST study. J Urol. 2022; 207(Supplement 5):e456. https:\/\/doi.org\/10.1097\/JU.0000000000002570.17.","DOI":"10.1097\/JU.0000000000002570.17"},{"issue":"6","key":"3104_CR25","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1200\/JCO.2022.40.6_suppl.012","volume":"40","author":"KN Chi","year":"2022","unstructured":"Chi KN, Rathkopf DE, Smith MR, Efstathiou E, Attard G, Olmos D, et al. Phase 3 MAGNITUDE study: first results of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination repair (HRR) gene alterations. J Clin Oncol. 2022;40(6):12. https:\/\/doi.org\/10.1200\/JCO.2022.40.6_suppl.012.","journal-title":"J Clin Oncol"},{"issue":"16","key":"3104_CR26","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.1200\/JCO.22.01649","volume":"41","author":"KN Chi","year":"2023","unstructured":"Chi KN, Rathkopf D, Smith MR, Efstathiou E, Attard G, Olmos D, et al. Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer. J Clin Oncol. 2023;41(16):3339\u201351. https:\/\/doi.org\/10.1200\/JCO.22.01649.","journal-title":"J Clin Oncol"},{"key":"3104_CR27","unstructured":"AKEEGA\u2122 (niraparib\/abiraterone acetate): prescribing information. August 2023. https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/AKEEGA-pi.pdf. Accessed December 2, 2024."},{"key":"3104_CR28","unstructured":"European Medicines Agency. Akeega (niraparib\/abiraterone acetate): Overview and product information. August 19, 2024. Amsterdam, The Netherlands. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/akeega. Accessed December 2, 2024."},{"key":"3104_CR29","unstructured":"European Medicines Agency. Zejula\u2014EPAR\u2014Public assessment report. Amsterdam, The Netherlands. September 14, 2017. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/zejula-epar-public-assessment-report_en.pdf. Accessed December 2, 2024."},{"issue":"12","key":"3104_CR30","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1007\/s40262-014-0178-6","volume":"53","author":"K Stuyckens","year":"2014","unstructured":"Stuyckens K, Saad F, Xu XS, Ryan CJ, Smith MR, Griffin TW, et al. Population pharmacokinetic analysis of abiraterone in chemotherapy-naive and docetaxel-treated patients with metastatic castration-resistant prostate cancer. Clin Pharmacokinet. 2014;53(12):1149\u201360. https:\/\/doi.org\/10.1007\/s40262-014-0178-6.","journal-title":"Clin Pharmacokinet"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03104-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03104-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03104-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T07:09:43Z","timestamp":1742713783000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03104-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,28]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["3104"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03104-y","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,28]]},"assertion":[{"value":"23 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Alberto Russu, Hui Tian, Nahor Haddish-Berhane, Juan Jose Perez Ruixo, and Muriel Boulton are employees of Johnson & Johnson and report stock or ownership interests for Johnson & Johnson. Anasuya Hazra was an employee of Johnson & Johnson at the time of study conduct and is now affiliated with Regeneron, and reports stock or ownership interests for Johnson & Johnson.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"For the study data included in this PPK analysis, study protocols and amendments were reviewed by independent ethics committees or institutional review boards and were conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with International Council for Harmonization Guideline for Good Clinical Practices and applicable regulatory requirements. Patients or their legally acceptable representatives provided written informed consent to participate in the studies.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}